AxSpA Podcast: Secukinumab retention over time & sacroiliac joint improvements between DMARDs




Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvements is sacroiliac joint symptoms across patients with AS and axSpA treated with different DMARDs.

Author Interview: Dr Jürgen Rech, 2024




Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jürgen Rech, a Senior Physician at the Friedrich-Alexander University of Erlangen-Nürnberg, as they discuss his recent paper ‘Abatacept Inhibits Inflammation and Onset of Rheumatoid Arthritis in Individuals at High Risk (ARIAA): A Randomised, International, Multicentre, Double-blind, Placebo-controlled Trial.’

PsA Podcast: Long-term safety of ixekizumab & bimekizumab treatment in a TNFi-IR population




Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the long-term safety of ixekizumab as well as bimekizumab treatment in a TNFi-IR population.

March 2024

Discussing Rheumatology: March 2024




Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that that add to the knowledge of common treatments relating to RA. In our first paper, Juergen Rech and colleagues present the results of the ARIAA study, which shows that abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. Our second paper is from Juergen Rech and colleagues, where they present the results of the ARIAA study which investigated whether abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. To access detailed summary slides for the papers discussed today, visit imidforum.com.

AxSpA Podcast: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment




Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs) and 24-month retention rates between patients with axSpA and PsA that were treated with secukinumab.

Discussing Rheumatology: February 2024




Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that show the long-term safety and efficacy of JAK inhibitors, both of which have a study period of 6.5 years. In our first paper, Roberto Caporali and colleagues show long-term safety and efficacy data for baricitinib as an RA therapy. Our second paper is from Christina Charles-Schoeman and her colleagues, where they present long-term data on the effect of upadacitinib on laboratory parameters in people with RA. To access detailed summary slides for the papers discussed today, visit imidforum.com.